Advertisement

Related Videos

Opening Session Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Apr
22
Today In Oncology
Pretreatment MRI Prognostic Information After Radical Prostatectomy
Early-Onset ICI-Related Myocarditis Linked to Increased Mortality
First-Line Zongertinib in Advanced HER2-Mutant NSCLC
Exposure to Wildfire Smoke May Be Linked to Increased Risk of Developing Several Types of Cancer
Intralesional Nivolumab May Be Effective Against Precancerous Oral Lesions
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo